Home
Conference Highlights
View All Conference Highlights
Year in Review / Wrap-Ups
Wrap-Ups
Year in Review
Contact Us
Conference Highlights
The European Hematology Association (EHA)
The European Hematology Association (EHA)
The
European Hematology Association
(
EHA
) is a non-governmental and not-for-profit membership organization that is guided by its mission to promote excellence in patient care, research, and education in hematology.
Ixazomib, Daratumumab, and Low-Dose Dexamethasone Induction in Frail Elderly Newly Diagnosed MM Patients
EHA 2020 – Multiple Myeloma
Induction with ixazomib, daratumumab, and low-dose dexamethasone in frail elderly newly diagnosed multiple myeloma patients in the HOVON 143 study was meaningfully effective regarding ORR and PFS, but with continued toxicity concerns.
Read More ›
Melflufen plus Dexamethasone in Patients with RRMM Refractory to Pomalidomide and/or an Anti-CD38 Monoclonal Antibody
EHA 2020 – Multiple Myeloma
Melflufen/dexamethasone demonstrated meaningful activity and manageable safety profile in patients with relapsed/refractory multiple myeloma who had ≥2 prior lines of therapy and were also refractory to pomalidomide and/or an anti-CD38 monoclonal antibody.
Read More ›
DREAMM-2: Belantamab Mafodotin in Relapsed/Refractory Multiple Myeloma – Prior Therapy Analysis
EHA 2020 – Multiple Myeloma
In the DREAMM-2 study of belantamab mafodotin in heavily pretreated relapsed/refractory multiple myeloma patients, comparable overall response rates (~30%) were observed between patients who had 3 to 6 prior therapies and those with ≥7.
Read More ›
Venetoclax vs Placebo in Combination with Bortezomib/Dexamethasone in Relapsed/Refractory Multiple Myeloma
EHA 2020 – Multiple Myeloma
Addition of venetoclax to bortezomib/dexamethasone in relapsed/refractory multiple myeloma patients (BELLINI phase 3 study) improves progression-free survival, but also results in higher mortality, with t(11;14) or
BCL2
high
gene expression patients benefiting most.
Read More ›
Defining and Predicting Unsustained Complete Remission in Transplant-Eligible Multiple Myeloma Patients
EHA 2020 – Multiple Myeloma
In patients with multiple myeloma who undergo frontline optimized induction followed by ASCT, MRD assessment and clinical response time kinetics were predictive of unsustained complete remission, based on a subgroup analysis of PETHEMA/GEM2012MENOS65.
Read More ›
Ixazomib in Combination with Lenalidomide and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma
EHA 2020 – Multiple Myeloma
An observational study of ixazomib plus lenalidomide/dexamethasone in relapsed/refractory multiple myeloma in French centers (REMIX) further defined the patient and disease characteristics and safety profile with this regimen; efficacy data are still maturing.
Read More ›
Pomalidomide plus Bortezomib/Dexamethasone Outcomes in Relapsed/Refractory Multiple Myeloma by Age, Prior Transplant, and High-Risk Cytogenetics
EHA 2020 – Multiple Myeloma
This pivotal trial (OPTIMISMM) subgroup analysis supports use of pomalidomide, bortezomib, and low-dose dexamethasone for lenalidomide-refractory patients regardless of age, prior stem-cell transplant status, or presence of high-risk cytogenetic abnormalities.
Read More ›
Venetoclax plus Daratumumab and Dexamethasone ± Bortezomib in Relapsed/Refractory Multiple Myeloma
EHA 2020 – Multiple Myeloma
An ongoing study of venetoclax plus daratumumab and dexamethasone ± bortezomib in patients with relapsed/refractory multiple myeloma demonstrated tolerable safety and clinically meaningful overall response rate (92%-96%), particularly among those with t(11;14).
Read More ›
Daratumumab plus Ixazomib/Dexamethasone as Second-Line in Multiple Myeloma Patients with Prior Lenalidomide Treatment
EHA 2020 – Multiple Myeloma
Addition of daratumumab to ixazomib/dexamethasone in second-line post-lenalidomide relapsed multiple myeloma (phase 1 portion of the ongoing DARIA study) resulted in a >70% overall response rate.
Read More ›
Isatuximab plus Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients with Plasmacytomas
EHA 2020 – Multiple Myeloma
Adding isatuximab to pomalidomide-dexamethasone treatment in RRMM patients with preexisting plasmacytomas resulted in improved median progression-free survival and rates of overall response and very good partial response with a manageable safety profile.
Read More ›
Page 1 of 5
1
2
3
4
5
Conference Correspondent Coverage is Brought to You by the Publishers of:
Learn more about our family of publications.
View Our Publications
Home
Conference Highlights
View All Conference Highlights
Year in Review / Wrap-Ups
Wrap-Ups
Year in Review
Contact Us